Cell & Gene Therapy Innovation Speakers
Chief Scientific and Technological Officer
Benoit Moreaux brings 20 years of industry expertise in strategic operations planning and execution, as well as global quality assurance.
Christian van den Bos
Dr. van den Bos current developed technology and IP dramatically enhancing the efficacy of mesenchymal stem cells, the productivity of cell culture media for primary cells and a novel drug target
Chief Scientific Officer
Laura Sepp-Lorenzino, Ph.D. is Chief Scientific Officer of Intellia Therapeutics. In this role, she oversees all drug research across in vivo and ex vivo (engineered cell therapy) areas.
Imperial College London
Dr Maria Papathanasiou is an appointed Lecturer at the Department of Chemical Engineering, Imperial College London (in effect April 2020).
Managing Director/Past Chair
Life Science Group Ltd/International Serum Industry Association
Jenny has over 30 years’ experience in the cell culture industry in the UK and worldwide and a track record in building successful SMCs. Jenny is the current owner of Life Science Group Ltd (LSG).
Founder and CEO
Dr. Karnieli earned his PhD in Biotechnology from the Sacler school of Medicine at Tel Aviv University and an MBA from the Haifa University school of management.
Chief Scientific Officer
Cellular Technology Limited
Magdalena is a Co-Founding Scientist and Chief Scientific Officer for CTL and Adjunct Associate Professor of Case Western Reserve University Department of Pathology.
Senior Consultant in Gene and Cell Therapies
NDA Group AB
Dr Houria Bachtarzi is a Senior Consultant, Regulatory Affairs - Gene and Cell Therapies, with a strong scientific and regulatory experience in the field of advanced biological therapies
Gene Therapy and Vector Manufacturing Specialist
Miltenyi Biotec SAS
Otto-Wilhelm MERTEN has a degree in biotechnology (Ph.D.) from the University of Life Sciences in Vienna, holds an HDR at the University of Evry/Val-d’Essonne and is Visiting Professor at ITQB/UNL.
Chief Executive Officer
Darrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started or invested in over 40 start-up life science, technology and social enterprises
Director, Business Development, Europe
Mio Muelthaler is on a mission to spread the news about a new fascinating disruptive nanofluidics based single-cell technology for gene therapy in EU.
Senior Director of European Public Policy
Alliance for Regenerative Medicine
Annie brings over 30 years of experience in European regulatory and government affairs, pricing, reimbursement and market access to the ARM Team.
Deputy Head, Applied Stem Cell Biology and Cell Technology
University of Leipzig
Dr. Shibashish Giri has more than 12 years’ experience in preclinical research and clinical therapy for cell, tissue and organ regeneration in Germany.